Histopathological Aspects as Predictor of Recurrency of Locally Advanced Breast Cancer

Kiki Akhmad Rizki, Teguh Marfen Djajakusumah, Hasrayati Agustina, Peri Hidayat

Abstract


The histopathological aspect of breast cancer has been established as one of the important prognostic factors of recurrence. This study aimed to determine whether histopathological examination can be used as a predictor of the incidence of recurrence in locally advanced breast cancer patients. This was a cohort retrospective observational study with a correlative analytical approach. Subjects of this study were breast cancer patients who have undergone mastectomy and/or received additional therapy at Dr. Hasan Sadikin General Hospital Bandung, Indonesia, between January 2017 and September 2019. Data were collected through medical records and anatomical histopathology data. Subjects were divided based on their recurrency status. A total of 62 breast cancer patients were included in the study with 31 recurrent patients and 31 non-recurrent patients. A total of 29 patients in the recurrent group (93.5%) had lymphovascular invasion. Histopathology grading showed a difference in both groups, in which recurrent group patients were mostly (74.2%) in the high histopathological grade while 51.6% of samples in non-recurrent group were categorized as moderate histopathological grade. Complete histopathological margins were found in both recurrent and non-recurrent groups for 54.8% and 87.1% respectively. There is a correlation between histopathologic grading, lymphovascular invasion, and incision margin with the recurrence of a locally advanced stage breast cancer. It can be concluded that some histopathological aspects can be used as a predictor of recurrence in locally advanced breast cancer.


Keywords


Breast cancer, histopathology, recurrency

Full Text:

PDF

References


  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
  2. Azhar Y, Agustina H, Abdurahman M, Achmad D. Breast cancer in west java: where do we stand and go?. Indonesian Journal of Cancer. 2020;14(3):91–6.
  3. Heer E, Harper A, Escandor N, Sung H, McCormack V, Fidler-Benaoudia MM. Global burden and trends in premenopausal and postmenopausal breast cancer: a population-based study. Lancet Glob Health. 2020;8(8):e1027–37.
  4. Garg PK, Prakash G. Current definition of locally advanced breast cancer. Curr Oncol. 2015;22(5):e409–10. doi:10.3747/co.22.269.
  5. Costa R, Hansen N, Gradishar WJ. Locally advanced breast cancer. In: The Breast. Elsevier; 2018:819-831.e6. doi:10.1016/B978-0-323-35955-9.00063-5
  6. Yulian ED, Yang AJ. Evaluation of Local advanced breast cancer following mastectomy: recurrence and influencing clinicohistopathology factors. The New Ropanasuri J Surg. 2016;1(1):3.
  7. Chopra S, Davies EL. Breast Cancer Facts and Figures. Medicine (United Kingdom). 2020;48(2):113–8.
  8. Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast. Philadelphia: Wolters Kluwer Health; 2014
  9. Rakha EA, Reis-Filho JS, Baehner F, Dabbs DJ, Decker T, Eusebi V, et al. Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res. 2010;12(4):207.
  10. Yoneto T, Hasumi K, Fujii Y, Takahasi N, Seki N, Yoshimoto T, et al. A patient with stage IIIB advanced breast cancer who is still alive 24 years after surgery: a case report and remarks on the treatment strategies. Transl Cancer Res. 2022;11(10):3903–11. doi:10.21037/tcr-22-1363
  11. Hoda SA. In ductal hyperplasia, usual and atypical. In: Hoda SA, Brogi E, Koerner FK, Rosen PP, editors. Rosen’s Breast Pathology. 5th ed. Wolters Kluwer; 2021.
  12. Li W, Zheng Y, Wu H, Li X. Breast-conserving therapy versus mastectomy for breast cancer: a ten-year follow-up single-center real-world study. Gland Surg. 2022;11(7):1148–65. doi:10.21037/gs-22-142
  13. Cheng L, Swartz MD, Zhao H, Kapadia AS, Lai D, Rowan PJ, et al. Hazard of recurrence among women after primary breast cancer treatment a 10-year follow-up using data from SEER-Medicare. Cancer Epidemiol Biomarkers Prev. 2012;21(5):800–9.
  14. Bundred JR, Michael S, Stuart B, Cutress RI, Beckmann K, Holleczek B, et al. Margin status and survival outcomes after breast cancer conservation surgery: prospectively registered systematic review and meta-analysis. BMJ. 2022;378:e070346. doi:10.1136/bmj-2022-070346
  15. Dai X, Li T, Bai Z, Yang Y, Liu X, Zhan J, et al. Breast cancer intrinsic subtype classification, clinical use and future trends. Am J Cancer Res. 2015;5(10):292–43.
  16. Tan PH, Ellis I, Allison K, Brogi E, Fox SB, Lakhani S, et al. The 2019 World Health Organization classification of tumours of the breast. Histopathology. 2020;77(2):181–5.
  17. Makki J. Diversity of breast carcinoma: histological subtypes and clinical relevance. Clinical Medicine Insights: Pathology. 2015;8:CPath.S31563.
  18. Fehrenbacher L, Capra AM, Quesenberry CP Jr, Fulton R, Shiraz P, Habel LA. Distant invasive breast cancer recurrence risk in human epidermal growth factor receptor 2-positive T1a and T1b node-negative localized breast cancer diagnosed from 2000 to 2006: a cohort from an integrated health care delivery system. J Clin Oncol. 2014;32(20):2151–8. doi:10.1200/JCO.2013.52.0858
  19. Liu X, Yuan P, Li R, Zhang D, An J, Ju J, et al. Predicting breast cancer recurrence and metastasis risk by integrating color and texture features of histopathological images and machine learning technologies. Comput Biol Med. 2022;146:105569. doi:10.1016/j.compbiomed.2022.105569
  20. Houssami N, Macaskill P, Marinovich ML, Morrow M. The association of surgical margins and local recurrence in women with early-stage invasive breast cancer treated with breast-conserving therapy: a meta-analysis. Ann Surg Oncol. 2014;21(3):717–30.




DOI: https://doi.org/10.15395/mkb.v56.3193

Article Metrics

Abstract view : 286 times
PDF - 112 times

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.


 


Creative Commons License
MKB is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License

 


View My Stats